CAR-T Cells Targeting Immune Checkpoint Pathway Players

Abstract

CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins. CAR-T cell therapy targeting checkpoint pathways is a promising therapy to decrease inhibitory signaling pathways. The review highlights future directions and perspectives in CAR-T cells targeting immune checkpoint pathways.

Trial registration: ClinicalTrials.gov NCT04213469 NCT04213469 NCT04185038 NCT04670068 NCT05241392 NCT04077866 NCT04662294.

Keywords: CAR-T cell; checkpoint; immunotherapy; review; tumor.

Conflict of interest statement

VG is an employee of Promab Biotechnologies. VG is serving as the guest editor of this journal. We declare that VG had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to GP.

© 2022 The Author(s). Published by IMR Press.